RxSight (RXST) opened Q1 2026 with revenue of US$30.9 million, a basic EPS loss of US$0.38, and a net income loss of US$15.9 million, setting a cautious tone for the quarter at a share price of US$5.80. Over recent periods the company has seen quarterly revenue move from US$40.2 million in Q4 2024 to a range between US$30.3 million and US$37.9 million across 2025. Basic EPS has remained negative between US$0.15 and US$0.29 in those quarters, keeping profitability firmly in loss making territory. For investors, the focus now turns to whether these new numbers point to any improvement in underlying margins or simply extend the pressure on the income statement.

See our full analysis for RxSight.

With the headline figures set, the next step is to line them up against the most common narratives around RxSight to see which views are supported by the data and which might need a rethink.

Losses Widen To US$15.9 Million On Lower LTM Revenue

• On a trailing twelve month basis, revenue moved from US$148.3 million in Q1 2025 to US$127.5 million in Q1 2026, while the loss over the same period grew from US$26.5 million to US$46.6 million.
• What stands out for a bearish view is that modest 7.2% annual revenue growth over the last year sits alongside losses that have increased at about 5.2% per year over five years,
  • bears highlight that forecasts pointing to earnings declining by an average of 3.4% per year for the next three years leave little sign in the recent LTM figures of a turn toward profitability,
  • and the step up in trailing loss from US$38.9 million in Q4 2025 to US$46.6 million in Q1 2026 adds weight to concerns about how quickly the business can absorb its cost base.

Revenue Growth Trails Market At 7.2% Per Year

• Over the last 12 months, revenue grew at 7.2% per year compared with an 11.4% pace for the broader US market, and quarterly revenue has sat between US$30.3 million and US$37.9 million across 2025 into Q1 2026.
• For a general market opinion that expects a clearer growth premium from a medical equipment stock, this slower top line trend creates a tension,
  • because the company is still loss making and forecasts indicate it is expected to remain unprofitable over the next three years even with this positive but slower revenue growth,
  • so investors weighing the 7.2% growth rate against the ongoing net losses of between US$5.9 million and US$15.9 million per quarter may focus more on revenue quality and margin progress than on headline growth alone.

Curious how numbers become stories that shape markets? Curious how numbers become stories that shape markets? Explore Community Narratives.

P/S Of 1.9x Sits Between Industry And Peer Averages

• The stock trades on a P/S of 1.9x, which is lower than the US Medical Equipment industry average of 2.8x but higher than the closer peer group average of 1.5x at a share price of US$5.80.
• For investors taking a cautious angle, this mixed valuation picture is backed up by the earnings profile,
  • because the company is still reporting quarterly EPS losses between US$0.15 and US$0.38 and trailing twelve month EPS of US$1.14 in losses,
  • while forecasts indicating continued earnings declines of around 3.4% per year help explain why the stock might trade at a discount to the wider industry yet still at a premium to direct peers.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on RxSight's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mixed tone around growth, losses and valuation, it helps to look past headlines and test the figures yourself while the latest results are fresh. To weigh these findings against potential downsides, take a closer look at the 2 important warning signs.

See What Else Is Out There

RxSight combines widening losses of US$46.6 million over the last twelve months with slower 7.2% revenue growth and a P/S multiple that does not clearly signal value.

If you want ideas where pricing looks more compelling relative to quality, use the 51 high quality undervalued stocks to quickly spot stocks that may offer a stronger risk reward trade off.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.